Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Will this WMIH message board still be active after the merger? If something were to happen, where is the backup message board for Escrow holders?
I'm loading up here before more eyes get on this.
Would any distributions to Escrow holders holders be required to pay taxes on those "earnings"? Would they just qualify as long term capital gains?
I'm adding more here... This is a great level to load up on shares.
Yea, I've seen some tweets about this one, there's definitely some buzz. I'm going to hop in at 0003.
Yup, This will get back to $3 in the blink of an eye. Smart money will be loading up here around a dollar.
Somebody slap the ask! This wants to run today.
Its on E*Trade
New PR this morning :
Signal Bay Has the Experience Needed to Capture California's Massive Cannabis Testing MarketFont
8:30 AM ET 11/29/16 | PR Newswire
Many Cannabis Testing Companies Fail to Achieve Accreditation. Many Others Simply Fail.
As of November 9, recreational marijuana is now legal in California. Signal Bay, Inc., a life sciences company focused on the exploding cannabis testing market which provides quality control testing for potency and contaminants in cannabis flower, extracts and edible products, stands to benefit significantly.
A subset of the overall marijuana market is the cannabis testing market, a space that is expected to grow exponentially as cannabis transitions from a formerly illegal substance to a legal and regulated consumer product. The testing market in the United States is expected to balloon to $850 million in size by 2020. In California alone, the market is expected to reach $300 million in 2017. Cannabis testing is critical to ensuring that cannabis, whether for medical or recreational use, is safe from pesticides, E. coli, molds, solvents and other toxins and impurities.
While many cannabis testing companies are currently vying for market share in this new wide open California market, strict regulations and mandatory cannabis testing accreditation have made it difficult for many inexperienced cannabis testing companies to survive. Only the experienced will thrive in this exploding, yet tight-knit, relationship-based industry. Signal Bay is one such experienced company.
Signal Bay's Oregon branch of EVIO Labs are currently accredited and setting the standard in the industry. Signal Bay currently has five EVIO Labs in operation including one in California. The Company plans to add 18 more accredited EVIO Labs in the Golden State by the end of 2018.
So what does cannabis testing laboratory accreditation entail?
Cannabis Testing Regulation and Accreditation in California
In 2015, California passed a bill (AB 266) requiring medical cannabis to be lab tested for regulatory purposes on or before July 1, 2017. The bill would make all companies involved in the production and sale of cannabis subject to meeting various standards set forth by the International Organization for Standardization, ISO/IEC. These requirements would also apply to third-party laboratories, engaged in marijuana testing. ISO requirements include state statutory environmental, agricultural, consumer protection, and food and product safety requirements, including sanitation standards, etc.
Here's What AB266 mandates, specifically:
-- The issuance, renewal, suspension, denial, and revocation of conditional licenses;
-- Procedures for appealing fines and the appeal of denial, suspension, or revocation of conditional licenses;
-- The application, licensing, and renewal forms and fees;
-- A time period in which the bureau shall approve or deny applications for a conditional license;
-- Qualifications for licensees;
-- Set standards for certification of testing laboratories to perform random sample testing of all medical marijuana.
Signal Bay's Experience with Accreditation Critical to Its Success in California
With a relatively high barrier to entry, and with more states looking to enact stricter testing regulations, many cannabis testing companies have fallen by the wayside. Even in Oregon, where cannabis has been legal for years, stricter testing regulations are impacting the cannabis testing industry in a significant way. In fact, Oregon currently has some of the strictest cannabis testing regulations of all the states in which recreational marijuana is legal, next to Nevada. The accreditation standard in Oregon, ORELAP, is more rigorous than the ISO 17025 standard that will be required in California. As the most experienced and the most dominant player in the Oregon cannabis testing space, Signal Bay understands what it takes to thrive in a robust regulatory environment.
"Many labs fail to ever become accredited," commented CEO of Signal Bay, William Waldrop. "Prior to October 1, when accreditation became mandatory for cannabis testing in Oregon, there were around 30 entities operating in the market that claimed to be full service testing labs. Now there are only 17 accredited labs performing testing services in Oregon and not all of these are actually operating."
"Many labs take up to a year to reach some level of accreditation, but fail to become fully accredited and remain unable to provide the full suite of services required for regulatory compliance. Many get stuck in the research and development stage after accreditation. At Signal Bay, however, our advanced technical experience as well as our experience and understanding of the regulatory system, enables us to get our EVIO Labs accredited and fully operational in a matter of months, rather than years."
Waldrop added that California, as well as other states which just recently legalized marijuana for recreational use (and states which recently approved medical use) are looking to states like Oregon as they build out their own regulatory structure.
Capturing California: The Signal Bay Way
Of all the cannabis testing companies jockeying for California market share, Signal Bay has a remarkable edge. The company's recent experience in the Oregon cannabis testing market as well as its unique business model make it a very strong player in the California market. It has developed a business model likened to Quest Diagnostics (NYSE:DGX), an industry leader in clinical laboratory services.
"It's the hub and spoke model," simplifies Waldrop. "In each state we will have centralized testing laboratories with other ancillary testing facilities in local markets statewide. The core centralized labs handles the bigger, high dollar testing functions while the smaller localized labs handle collection, sampling, and other testing services. Couriers move back and forth between locations and the hub, maximizing efficiency. This enables us to develop networks of testing laboratories that operate efficiently within each state. Over time the ancillary testing facilities can become more specialized, increasing overall capacity and allowing for reduced downtime of services, even if a critical piece of equipment is out of service at the hub."
This model is critical to reaching economies of scale while not getting bogged down by increasing regulations and the difficulty and time it takes to acquire accreditation.
"Other companies may get bogged down just getting one lab accredited and may temporarily shut down if new regulations require some kind of change or new form of testing," explained Waldrop. "But with our model it is very different. Our experienced team can focus resources efficiently to accommodate any regulatory changes that may come without stalling our business. As long as at least one location is capable of upgrading quickly, all of our locations in that area can continue operation without downtime. Our model enables us to remain incredibly flexible in a volatile and quickly evolving market."
For example, if some new testing requirement was suddenly required, a company with a stand-alone lab would have to potentially reduce throughput or temporarily close to upgrade the lab in order to retain its operational capacity and retain market share whereas Signal Bay would only have to upgrade the "hub" within that geographical area of operation.
"But it's not just about getting through accreditation," said Waldrop, "It's not just paperwork. It's also about having qualified competent scientists that can ensure we are providing the highest level of technical service possible. We find ourselves very fortunate and well positioned in that regard as well."
Many cannabis testing labs struggle to survive simply because they lack proper technical expertise, but this is no issue for Signal Bay. Chief Science Officer and natural products researcher, Dr. Anthony Smith leads the scientists of Signal Bay's EVIO Labs. Dr. Smith is a well respected biochemist and researcher, holding a PhD in Molecular and Cellular Biology from Oregon State University. Dr. Smith held a position on the Oregon governor's Task Force for Researching the Medical and Public Health Effects of Cannabis and serves on the scientific advisory board of the Health Research Institute, a non-profit horticultural and medical research group.
Waldrop went on to explain: "Our technical leadership from each of our laboratory directors and our Chief Science Officer affords us a unique advantage in the California market. We know our way around accreditation and we are some of the best at what we do. Our team is interested not only in producing reliable data for our clients, but our scientists are capable and interested in innovating new techniques, contributing to national and international cannabis research, enhancing public health and safety, and educating producers and consumers."
Signal Bay's Golden State Opportunity
California's $300 million cannabis market is largely up for grabs. There will be many companies in the growing cannabis testing industry that will try to capitalize on this opportunity. With its deep experience, close industry and government relationships, and unique business model, Signal Bay is poised to replicate its success in Oregon and become one of the Golden State's most dominant players.
Thanks for the quick reply, I wasn't aware of that statement.
Serious question... Is anyone here concerned about a possible reverse split?
Today we had a 3000+ percent increase in volume over the last ten day average. I think its fair to say the word has leaked out that something significant is on the horizon. IMO.
The PR came out yesterday :
NuLegacy Intersects Higher Grade Gold Mineralization
RENO, NEVADA--(Marketwired - Sep 7, 2016) - NuLegacy Gold Corporation (TSX VENTURE:NUG)(NULGF) reports assay results from five reverse circulation holes drilled during August in its 100% owned Iceberg oxide gold deposit. The primary target is the shallow Carlin-style oxidized gold mineralization within the 3 km long and 0.5 km wide Iceberg gold deposit in the Cortez gold-trend of north-central Nevada.
Highlights from the infill and step-out drilling expanding the North zone of the Iceberg include:
2.16 grams per tonne gold over 21.3 meters (70 ft.) including 6.09 g/t gold over 4 .6 meters in RHB- 82,
1.63 g/t gold over 10.7 m and 0.59 g/t gold over 24.4 m in RHB-83,
1.28 g/t gold over 18.3 m including 2.36 g/t gold over 7.6 m in RHB-84.
"Intervals of consistent gold mineralization that have core intervals of substantially higher grade, as in holes RHB-82 and 84, are typical features of Carlin-type gold deposits", comments Dr. Roger Steininger, NuLegacy's CGO, "and are a strong indication that additional drilling will continue to expand the Iceberg deposit."
Holes RHB-82 and 83 are the two most southerly holes drilled to date in the North zone and continue the progress towards filling the gap between the North and Central zones of the Iceberg deposit. The gold mineralization is hosted predominately in Devonian silicified limestone breccia that is strongly oxidized and similar to the mineralized zones in the Cortez gold trend's other major gold deposits.
Two just completed wildcat holes drilled into the Avocado and IRC anomalies are in for assay; as well we are half way through a $100,000 - 10 line CSAMT and IP survey program covering the entire Iceberg gold deposit. This is expected to greatly enhance our targeting ability once completed and analyzed.
Does anyone have a count of how many escrow shared are out there?
Just logged into a long dormant account and see that I have had 10 shares of WMIH placed in it... Price paid $0.00
Can anyone give me a quick summary? I sold out of wamuq long ago during the chaos. This account also shows 17,655 shares of a wamaq escrow cusip valued at 0.
Thanks.
Looks like 100,000 block went thru premarket. Up 10% right off the bat, looks like there is still buying pressure.
No, significant data on the phase 1 trialwill be released very soon per our interim CEO and one of our Dr's at the retinal conference this past weekend.
I just added, hit the ask at .08 . Good luck today
I just added, hit the ask at .o8
good luck!
I think people in the know have information that the Top line data will be released this Thursday in the New England Journal of Medicine. Just my opinion.
No PR. Just the news about article in NEJM and seeking alpha.
There will be some resistance at .08 , after that it is blue skies, next resistance would be mid .20's I believe.
We may hit .08s within the hour ...
Here is a post a made on another forum yesterday :
Gary Rabin is out as CEO, the CFO Edward Myles has been appointed interim President, as the board searches for a replacement. This is a net positive for the company as Mr. Rabin was under scrutiny by the SEC for not reporting sales of stock, and that investigation could have held ACTC back from up listing to the NASDAQ, or receiving financing from non dilutive sources.
Former CEO Rabin hinted in the past the ACTC would release "Top Line Data" in the future, hopefully by the end of 2013. Well, that did not come to pass, but at the recent Biotech showcase conference in California on 1/13/14 Myles stated the the data would be released in the very near future.
This Data is very important for the company, it will be a summary of the 30+ patients injected to date. More or less a summary of all Phase 1. This data will not only impact the share price as they surge till phase II this year, it will also allow them to either joint venture a program for upfront cash to finish trials, or obtain favorable terms on financing from the private sector.
At the Euretina (European Society of Retina Specialist) Conference yesterday (1/25/14) Dr. Hubschman let it slip that ACTC will have findings published in the New England Journal of Medicine, very soon. This may be the same Top Line Data that both Rabin and Myles have referred to in the past. The journal is a weekly release, so this could be released at any time.
Some other new info found at the Euretina conference is one we have been teased with before. That, "all the patients had some functional improvement". So, from what I infer from this is every patient injected either had a visual acuity improvement, or a halt in the progression of the disease. This is Huge.
Onto The FDA's fast track designation and FDA Breakthrough Status . You can read about them here:
http://www.fda.gov/regulatoryinformation/legislation/federalfooddrugandcosmeticactfdcact/significantamendmentstothefdcact/fdasia/ucm341027.htm
http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/speedingaccesstoimportantnewtherapies/ucm128291.htm
It is known that a BioTech company has been recently granted Breakthrough status, but that company has not yet come forward. Many speculate that this company is indeed ACTC. Fast track designation seems to be in the bag, given the prelim data from phase 1, but breakthrough status would be a game changer. Or even perhaps the news of the fast track and breakthrough could be released in the New England Journal of Medicine article?
The stocks volume has been on the rise this past week, and there are several more signs that some big things may transpire soon. On 1/24/14 Nature magazine released what I would label a "bash" article regarding the finances of ACTC. Which raise some questions, they are a scientific journal that rarely focus on the money side of things. Seems as if they may have an ulterior motive for the article:
http://www.nature.com/news/stem-cell-company-in-crisis-1.14591
In contrast to that, Seeking Alpha released a article today, "Advanced Cell Tech Will Make You Rich in 2014"
http://seekingalpha.com/article/1968271-read-my-lips-advanced-cell-technology-will-make-you-rich-in-2014?source=email_rt_article_readmore
While I agree with most of this piece of writing, it can be seen as a "pump" article.
With the shares we have approved we have enough funding to make it through 2014, but at some point this year, perhaps soon, we will need to acquire more funding. The question is will it be dillutive or not. Will it be infused cash from a JV partner? Or more shares authorized? With the impending news, the stock may rise to a level in which it would be reasonable to pull the trigger on the Reverse Split that shareholders approved last year. At which point we could uplist to the Nasdaq and have some solid institutional investors flock to the company.
Or, is the news of :
Significant top line data
Article in the NEJM
Breakthrough status
Fastrack status
Start of Phase II
Enough to raise the stock price to a point where ACTC will not need to reverse split?
Regardless, exciting things are on the horizon for Advanced Cell Technology. Good luck.
Thank you so much, didn't know this option was available.
Some very interesting tidbits in the interview with GR in todays seeking alpha article...
He has pretty much ruled out a joint venture with the RPE program, it seems ACTC will protect their most valued asset for now.
So, we can expect to see a small jv with one of our other programs before the end of the year IMO, possibly before the shareholder meeting later this summer... I'm not sure even GR knows yet which program will get the jv. Could be any of them : photoreceptor progenitors, platelets, mesenchymal stem cells etc...
With the shelf registration filed for 35 million, it would be strange to then sign onto a massive jv for the RPE program pottentialy worth billions.
I see it as ACTC is preparing to go it alone if necessary all the way through Phase II, there will be dilution, but the company and hence the shareholders will be better rewarded when we get to commercialization, as opposed to signing away a substantial percentage of our future earnings to Pfizer or Merk.
The question is, will a small jv later this summer, perhaps timed well with a publication of data, be enough to move our PPS high enough for a less painfull Reverse split?
Correct, they actually have a backup plan and have thought ahead... Thats a good sign.
IMO the fact that phaseI can be ended before schedule and that the 200k cohort may not even be needed, says it all.
I'm marking my calender for the shareholder meeting this summer, thats my new target date for more data (cohort results, new publication of findings, jv, NIH, RS, platelets update, uplist etc) IMO
He did mention the form 4's ... He said the situation is currently being reviewed by the board, and he cant say anything else until their complete.IMO could go either way.
Lot of good stuff :
- Early termination of phaseI , moving along quicker : fast track
- Gary met with Sen. Warren yesterday about the NIH approval
- Animal/Vet treatment in future for more earnings
- More institutions for cohort 2a within 2 weeks
- CFO seems to be in place
- SEC settlement very soon (before shareholder meeting in AUG?)
Modification of Series A-1 Convertible Redeemable Preferred Stock:
On October 19, 2009, the Company entered into two letter agreements with Volation, pursuant to which (i) the Company reduced the conversion price of its existing outstanding Series A-1 convertible preferred stock issued to Volation to $.10 per share resulting in 22,880,000 shares of Common Stock upon conversion, (ii) the Company issued Volation 2,500,000 shares of its Common Stock at $0.10 per share in payment of an outstanding commitment fee, and (iii) Volation waived the delinquency in non-payment of the $250,000 commitment fee required pursuant to the preferred stock purchase agreement between the Company and Volation. The commitment fee was paid during the year ended December 31, 2010 by reducing the proceeds paid by the Series A-1 Preferred Stock investors by the amount of the commitment fee.
Todays 8k for shares to Volation capital originated in 2009... Thats when the agreement was entered.
New SA Article...
Swinging For The Fences With Advanced Cell Technology
May 1 2013, 14:07
http://seekingalpha.com/article/1389991-swinging-for-the-fences-with-advanced-cell-technology
In a private email to an investor a week or so ago, I believe he stated his reason for selling such a large number of shares was that he was going through a divorce and needed the cash... Whether or not anyone will trust that statement or not is up to them.
Cant find the link to the email but it was on icell.
Stem Cells: Dreamers, Fools, And The Valley Of Death
http://seekingalpha.com/article/1372241-stem-cells-dreamers-fools-and-the-valley-of-death
A few mentions of ACTC in the article...
Thanks for the heads up, i'm going to do some DD on this before I jump in.
Hey guys, I've been out of Genta for several years, ever since there RS after the bad news from the FDA about genesense (maybe 2008?)... Just started looking at it again. But once again there share structure is just dismal.
I'm thinking about buying some, but is anyone brave enough to hold this longterm? Any wispers about when the next RS could take place? TIA
Seeking Alpha
Seeing Is Believing, The Future Of ACTC
Feb 23, 2012 1:06 PM
http://seekingalpha.com/instablog/982895-benji687/337911-seeing-is-believing-the-future-of-actc